Published in PLoS Med on December 01, 2006
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One (2013) 4.31
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A (2009) 2.84
Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res (2012) 2.54
BH3-only proteins in apoptosis and beyond: an overview. Oncogene (2008) 2.13
New molecularly targeted therapies for lung cancer. J Clin Invest (2007) 1.86
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One (2007) 1.86
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59
Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum (2009) 1.56
Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol (2010) 1.53
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med (2010) 1.46
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res (2013) 1.46
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest (2007) 1.41
MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis (2012) 1.40
Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol (2011) 1.32
PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinforma (2013) 1.28
Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One (2012) 1.28
BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene (2008) 1.23
BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells. Oncogene (2007) 1.22
Efficiency analysis of competing tests for finding differentially expressed genes in lung adenocarcinoma. Cancer Inform (2008) 1.21
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res (2010) 1.21
Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med (2010) 1.19
Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One (2010) 1.17
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Microarray meta-analysis database (M(2)DB): a uniformly pre-processed, quality controlled, and manually curated human clinical microarray database. BMC Bioinformatics (2010) 1.05
Can survival prediction be improved by merging gene expression data sets? PLoS One (2009) 1.04
A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One (2009) 1.03
Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med (2008) 1.03
An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics (2008) 1.02
Genetic susceptibility to lung cancer--light at the end of the tunnel? Carcinogenesis (2013) 1.00
PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer (2013) 0.99
The incredible shrinking world of DNA microarrays. Mol Biosyst (2008) 0.98
Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. Cancer Res (2011) 0.97
A novel network model identified a 13-gene lung cancer prognostic signature. Int J Comput Biol Drug Des (2011) 0.96
Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res (2009) 0.96
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients. PLoS One (2012) 0.93
Research status and funding trends of lung cancer biomarkers. J Thorac Dis (2013) 0.93
Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia. Int J Oncol (2012) 0.91
Iterative Bayesian Model Averaging: a method for the application of survival analysis to high-dimensional microarray data. BMC Bioinformatics (2009) 0.89
Molecular signatures of metastasis in head and neck cancer. Head Neck (2008) 0.89
Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol (2014) 0.87
CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour Biol (2014) 0.87
Highlight report: Validation of prognostic genes in lung cancer. EXCLI J (2014) 0.86
Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS One (2013) 0.85
Test on existence of histology subtype-specific prognostic signatures among early stage lung adenocarcinoma and squamous cell carcinoma patients using a Cox-model based filter. Biol Direct (2015) 0.85
Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Oncologist (2012) 0.85
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J (2009) 0.84
Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics (2011) 0.84
Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol (2009) 0.84
Identification of reproducible gene expression signatures in lung adenocarcinoma. BMC Bioinformatics (2013) 0.84
SPARCoC: a new framework for molecular pattern discovery and cancer gene identification. PLoS One (2015) 0.84
A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics (2014) 0.83
Relation between smoking history and gene expression profiles in lung adenocarcinomas. BMC Med Genomics (2012) 0.83
High-dimensional genomic data bias correction and data integration using MANCIE. Nat Commun (2016) 0.82
Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma. BMC Genomics (2009) 0.82
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Transl Lung Cancer Res (2013) 0.82
Robust meta-analysis of gene expression using the elastic net. Nucleic Acids Res (2015) 0.82
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Int J Oncol (2015) 0.81
p85α is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res (2015) 0.81
The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev (2008) 0.81
A white-box approach to microarray probe response characterization: the BaFL pipeline. BMC Bioinformatics (2009) 0.81
LTR: Linear Cross-Platform Integration of Microarray Data. Cancer Inform (2010) 0.81
Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. Sci Rep (2015) 0.81
Cancer research: from prognostic genes to therapeutic targets. EXCLI J (2014) 0.81
Kernelized partial least squares for feature reduction and classification of gene microarray data. BMC Syst Biol (2011) 0.80
Identification of Subtype-Specific Prognostic Genes for Early-Stage Lung Adenocarcinoma and Squamous Cell Carcinoma Patients Using an Embedded Feature Selection Algorithm. PLoS One (2015) 0.80
The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer. Oncotarget (2016) 0.78
Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma. BMC Med Genomics (2014) 0.78
Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics (2016) 0.77
How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol (2011) 0.77
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics (2008) 0.77
Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma. Oncotarget (2016) 0.77
Microarray Meta-Analysis and Cross-Platform Normalization: Integrative Genomics for Robust Biomarker Discovery. Microarrays (Basel) (2015) 0.76
Yin Yang gene expression ratio signature for lung cancer prognosis. PLoS One (2013) 0.76
Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer. J Probab Stat (2012) 0.76
An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer. Oncotarget (2016) 0.76
The mitotic checkpoint regulator RAE1 induces aggressive breast cancer cell phenotypes by mediating epithelial-mesenchymal transition. Sci Rep (2017) 0.75
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. Oncotarget (2016) 0.75
Prognostic factors in resected lung carcinomas. EJC Suppl (2013) 0.75
Survival impact index and ultrahigh-dimensional model-free screening with survival outcomes. Biometrics (2016) 0.75
Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients. J Exp Clin Cancer Res (2017) 0.75
Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays (Basel) (2013) 0.75
Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. J Cancer (2017) 0.75
Sex-Specific Associations between Particulate Matter Exposure and Gene Expression in Independent Discovery and Validation Cohorts of Middle-Aged Men and Women. Environ Health Perspect (2016) 0.75
Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients. PLoS One (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res (2003) 14.37
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Regional lymph node classification for lung cancer staging. Chest (1997) 5.13
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Variation in gene expression patterns in human gastric cancers. Mol Biol Cell (2003) 2.39
Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer (1997) 1.97
Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. Bioinformatics (2005) 1.91
One hundred years of lung cancer. Am J Respir Crit Care Med (2005) 1.90
Partial Cox regression analysis for high-dimensional microarray gene expression data. Bioinformatics (2004) 1.90
MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res (2004) 1.77
Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol (2004) 1.62
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A (2003) 1.53
MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol (2005) 1.50
Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol (2005) 1.48
Screening for lung cancer: a review of the current literature. Chest (2003) 1.46
A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res (2003) 1.36
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol (2006) 1.33
Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene (2001) 1.17
Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med (2004) 1.16
FLT3: receptor and ligand. Growth Factors (2004) 1.07
Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res (2005) 1.00
Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism (2005) 1.00
Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol (2005) 0.99
Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? Mol Cancer (2004) 0.96
Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene (2002) 0.95
Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer (2002) 0.94
Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer (2005) 0.90
Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer (2005) 0.87
Distribution of Bcl-2 gene expression and its prognostic value in non-small cell lung cancer. Tuberk Toraks (2005) 0.86
Characteristics of long-term survivors of untreated lung cancer. Lung Cancer (2002) 0.83
New therapeutic approaches for early stage non-small cell lung cancer. Surg Oncol (2005) 0.82
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell (2006) 7.49
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Lung cancer in never smokers: a review. J Clin Oncol (2007) 5.49
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Spreading the word. Nature (2007) 5.03
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet (2004) 4.95
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS. J Clin Oncol (2009) 4.53
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol (2008) 3.02
Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park) (2010) 2.95
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74
The Drosophila nuclear receptor e75 contains heme and is gas responsive. Cell (2005) 2.73
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72
Relationship of obesity with osteoporosis. J Clin Endocrinol Metab (2007) 2.71
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol (2008) 2.71
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol (2009) 2.64
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol (2011) 2.50
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest (2004) 2.44
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol (2005) 2.37
Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet (2009) 2.35
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Lung cancer in China: challenges and interventions. Chest (2013) 2.31
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics (2013) 2.27
IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet (2008) 2.27
DGIdb: mining the druggable genome. Nat Methods (2013) 2.26
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell (2006) 2.24
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. Oncology (Williston Park) (2013) 2.16
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol (2011) 2.15
The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J (2012) 2.13
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10
Hotelling's T2 multivariate profiling for detecting differential expression in microarrays. Bioinformatics (2005) 2.10
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
A high performance test of differential gene expression for oligonucleotide arrays. Genome Biol (2003) 2.03
Tumor susceptibility of Rassf1a knockout mice. Cancer Res (2005) 2.03
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res (2005) 2.02
Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. Clin Chem (2006) 2.00
Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. J Clin Oncol (2010) 2.00
Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg (2007) 1.99
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93
Differential prognostic impact of comorbidity. J Clin Oncol (2004) 1.92
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res (2007) 1.91